Drug Trial Radar · NCT00827788
Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
432
Planned (sponsor's estimate)
Start
Dec 2008
Primary completion
Apr 2010
Sponsor
- Lead sponsor
- Ospedale San DonatoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ospedale Le Scotte; Ospedale della Misericordia - Grosseto
- First posted
- Jan 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the incidence of contrast induced nephropathy and myocardial tissue reperfusion following iso-osmolar iodixanol or ipo-osmolar iopromide administration in patients with acute myocardial infarction undergoing primary PCI.
Conditions
- Contrast Induced Nephropathy
- Acute Myocardial Infarction
Interventions
IodixanolDrug
Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
IopromideDrug
Low-osmolar contrast medium (Iopromide) will be administered during PCI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Contrast Induced Nephropathy (CIN) between the two study groups, defined as relative increase of serum Creatinine of 25% or more from basal valuesTime frame: days 1, 2, 3, and at discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cardiovascular Department, Ospedale S.Donato
Arezzo, AR, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.